Skip to content
The Policy VaultThe Policy Vault

Lenvima (lenvatinib) — Medica

Hepatocellular carcinoma

Initial criteria

  • age ≥ 18 years
  • Patient has unresectable or metastatic disease
  • Medication is used as first-line therapy

Approval duration

1 year